688331 荣昌生物
已收盘 09-30 15:00:00
资讯
新帖
简况
港股异动 | 荣昌生物(09995)尾盘涨超3% 泰它西普治疗gMG中国Ⅲ期临床研究分析结果在AANEM年会公布
智通财经 · 09-30 15:49
港股异动 | 荣昌生物(09995)尾盘涨超3% 泰它西普治疗gMG中国Ⅲ期临床研究分析结果在AANEM年会公布
荣昌生物（688331）披露公司秘书及授权代表变更公告，9月28日股价下跌0.81%
证券之星 · 09-28
荣昌生物（688331）披露公司秘书及授权代表变更公告，9月28日股价下跌0.81%
荣昌生物：谭栃如辞去联席公司秘书等职位
南方财经网 · 09-28
荣昌生物：谭栃如辞去联席公司秘书等职位
9月24日荣昌生物跌6.79%，万家行业优选LOF基金重仓该股
证券之星 · 09-24
9月24日荣昌生物跌6.79%，万家行业优选LOF基金重仓该股
9月21日荣昌生物涨8.85%，万家行业优选LOF基金重仓该股
证券之星 · 09-21
9月21日荣昌生物涨8.85%，万家行业优选LOF基金重仓该股
荣昌生物涨8.85%，东海证券二周前给出“买入”评级
证券之星 · 09-21
荣昌生物涨8.85%，东海证券二周前给出“买入”评级
每周股票复盘：荣昌生物（688331）上半年营收增433.11%
证券之星 · 09-20
每周股票复盘：荣昌生物（688331）上半年营收增433.11%
荣昌生物：9月16日召开业绩说明会
证券之星 · 09-18
荣昌生物：9月16日召开业绩说明会
康方生物迎大敌：荣昌生物RC148亮相世界肺癌大会 预计峰值销售额约36亿元
新浪证券 · 09-17
康方生物迎大敌：荣昌生物RC148亮相世界肺癌大会 预计峰值销售额约36亿元
股市必读：荣昌生物新发布《H股公告》
证券之星 · 09-14
股市必读：荣昌生物新发布《H股公告》
每周股票复盘：荣昌生物（688331）上半年净利46.6亿扭亏为盈
证券之星 · 09-13
每周股票复盘：荣昌生物（688331）上半年净利46.6亿扭亏为盈
【私募调研记录】巨杉资产调研云天励飞、荣昌生物
证券之星 · 09-09
【私募调研记录】巨杉资产调研云天励飞、荣昌生物
【私募调研记录】保银投资调研荣昌生物
证券之星 · 09-09
【私募调研记录】保银投资调研荣昌生物
荣昌生物：8月25日召开分析师会议，华泰证券、国联民生等多家机构参与
证券之星 · 09-09
荣昌生物：8月25日召开分析师会议，华泰证券、国联民生等多家机构参与
股市必读：荣昌生物新发布《荣昌生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》
证券之星 · 09-09
股市必读：荣昌生物新发布《荣昌生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》
荣昌生物：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
证券日报网 · 09-07
荣昌生物：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
东海证券：给予荣昌生物买入评级
证券之星 · 09-04
东海证券：给予荣昌生物买入评级
荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%
证券之星 · 09-02
荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%
荣昌生物(09995)：截至8月末累计回购4.1万股A股
智通财经 · 09-02
荣昌生物(09995)：截至8月末累计回购4.1万股A股
执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元
智通财经 · 09-02
执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC118、RC278、RC288。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":117.34,"timestamp":1790751600000,"preClose":116.67,"halted":0,"volume":6898354,"delay":0,"changeRate":0.0057,"floatShares":356000000,"shares":564000000,"eps":10.3131,"marketStatus":"已收盘","change":0.67,"latestTime":"09-30 15:00:00","open":116,"high":120.42,"low":113.68,"amount":809000000,"amplitude":0.0578,"askPrice":117.35,"askSize":25,"bidPrice":117.34,"bidSize":36,"shortable":0,"etf":0,"ttmEps":10.3131,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":116.67,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":128.34,"lowLimit":105,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":7.97,"roa":"--","peRate":11.377762,"roe":"78.38%","epsLYR":1.29,"committee":0.513859,"marketValue":66236000000,"turnoverRate":0.0194,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","afterMarket":{"amount":82138,"volume":700,"close":117.34,"buyVolume":1076,"sellVolume":0,"time":1790753637746,"indexStatus":"已收盘 09-30 15:30:00","preClose":116.67},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":72.9,"timestamp":1790928489009,"preClose":77.1,"halted":0,"volume":949394,"delay":0,"premium":"-46.91"},"floatMarketCap":41761000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2671727907","title":"港股异动 | 荣昌生物(09995)尾盘涨超3% 泰它西普治疗gMG中国Ⅲ期临床研究分析结果在AANEM年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2671727907","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671727907?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:49","pubTimestamp":1790754545,"startTime":"0","endTime":"0","summary":"消息面上，据荣昌生物官微消息，9月29日，荣昌生物泰它西普治疗全身型重症肌无力中国Ⅲ期临床研究的一项最新事后分析结果，在2026年美国神经肌肉与电诊断医学协会年会期间的重症肌无力基金会科学会议上，以口头报告形式公开发布。近期，Vor Bio宣布泰它西普治疗gMG的全球Ⅲ期临床研究已完成患者入组，该研究24周主要终点的顶线结果预计于2027年上半年公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2328871848.SGD","BK1574","LU1969619763.USD","KCAI","BK4585","VXUS","BK0239","LU1064131003.USD","688331","09995","BK1583","LU2148510915.USD","LU2488822045.USD","BK1161","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670536032","title":"荣昌生物（688331）披露公司秘书及授权代表变更公告，9月28日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670536032","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670536032?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:07","pubTimestamp":1790604469,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，荣昌生物报收于115.34元，较前一交易日下跌0.81%，最新总市值为651.07亿元。近日，荣昌生物发布公告称，董事会宣布童少靖先生已获香港联交所确认具备担任公司秘书的资格。谭柏如女士已辞任公司联席公司秘书及根据上市规则第3.05条委任的授权代表，自2026年9月28日起生效。谭女士将继续担任公司条例项下在香港接受法律程序文件的授权代表。董事会对谭女士的贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","BK1583","LU1064131003.USD","LU1969619763.USD","LU1064130708.USD","LU2488822045.USD","BK1161","BK1574","LU2328871848.SGD","688331","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670028042","title":"荣昌生物：谭栃如辞去联席公司秘书等职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2670028042","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670028042?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:38","pubTimestamp":1790584680,"startTime":"0","endTime":"0","summary":"南财智讯9月28日电，荣昌生物（09995.HK）公告，谭栃如辞任公司联席公司秘书及授权代表，自2026年9月28日起生效。童少靖获委任为授权代表，并留任公司唯一公司秘书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885235355.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885235355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","BK1161","LU1064131003.USD","LU2488822045.USD","LU2328871848.SGD","09995","BK1583","BK1574","LU2148510915.USD","BK0239","688331","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463901","title":"9月24日荣昌生物跌6.79%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463901","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463901?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:38","pubTimestamp":1790239117,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日荣昌生物跌6.79%，收盘报116.28元，换手率2.01%，成交量7.15万手，成交额8.48亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共122家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1969619763.USD","BK1583","LU2148510915.USD","LU2488822045.USD","09995","BK1161","160916","688331","LU2328871848.SGD","BK1574","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669615960","title":"9月21日荣昌生物涨8.85%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669615960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669615960?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980142,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日荣昌生物涨8.85%，收盘报125.0元，换手率3.02%，成交量10.74万手，成交额13.19亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共122家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","160916","BK1161","BK0239","09995","LU2488822045.USD","LU2328871848.SGD","688331","LU2148510915.USD","LU1969619763.USD","BK1574","BK1583","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669607159","title":"荣昌生物涨8.85%，东海证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669607159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669607159?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980130,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨8.85%，收盘报125.0元。2026年9月4日，东海证券研究员杜永宏发布了对荣昌生物的研报《公司简评报告：业绩亮眼，研发国际化加速推进》，该研报对荣昌生物给出“买入”评级。公司核心产品持续放量，研发国际化快速推进，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国泰海通的廖博闻、余文心、余克清。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906290","title":"每周股票复盘：荣昌生物（688331）上半年营收增433.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906290","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906290?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:24","pubTimestamp":1789838654,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，荣昌生物报收于114.84元，较上周的114.72元上涨0.1%。本周，荣昌生物9月14日盘中最高价报119.3元。本周关注点来自业绩披露要点：2026年上半年公司总营业收入58.53亿元，同比增长433.11%。答：2026年上半年,公司的核心产品销售收入持续放量,实现销售收入13.4亿元,同比增长22.3%;总营业收入58.53亿元,同比增长433.11%。截至2026年6月30日,累计获得发明专利授权187项,实用新型专利授权37项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919551","title":"荣昌生物：9月16日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919551?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:06","pubTimestamp":1789697204,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月17日荣昌生物发布公告称公司于2026年9月16日召开业绩说明会。荣昌生物2026年中报显示，上半年度公司主营收入58.53亿元，同比上升433.11%；归母净利润46.62亿元，同比上升1137.06%；扣非净利润43.38亿元，同比上升1073.78%；其中2026年第二季度，公司单季度主营收入51.97亿元，同比上升808.6%；单季度归母净利润43.34亿元，同比上升2317.88%；单季度扣非净利润43.73亿元，同比上升2360.61%；负债率15.57%，投资收益128.7万元，财务费用2449.79万元，毛利率95.71%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800008974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","688331","LU1969619763.USD","09995","LU2328871848.SGD","LU2148510915.USD","BK1583","LU1064131003.USD","LU2488822045.USD","LU1064130708.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668959205","title":"康方生物迎大敌：荣昌生物RC148亮相世界肺癌大会 预计峰值销售额约36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959205","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668959205?lang=zh_cn&edition=full","pubTime":"2026-09-17 14:17","pubTimestamp":1789625820,"startTime":"0","endTime":"0","summary":"9月15日，荣昌生物与艾伯维联合开发的PD-1/VEGF双抗RC148一线治疗鳞状和非鳞状非小细胞肺癌的II期临床数据以口头报告形式在世界肺癌大会亮相。基于以上参数计算，RC148 大中华区峰值年销售额约为 36 亿元。从时间维度来看，RC148 预计 2030 年左右获批上市，通常创新药上市后需经历 5-7 年的市场爬坡期达到销售峰值，预计 2036 年左右达到峰值销售额，距离当前时点约 10 年。结合 0.50 的临床成功概率，最终 RC148 大中华区管线的风险调整净现值约为 5.6 亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-17/doc-iniscksf0292708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348827113.USD","LU2778985437.USD","LU0540923850.HKD","LU2476274308.USD","LU0417516571.SGD","BK0239","LU1064130708.USD","LU1720050803.USD","LU2399975544.HKD","LU2148510915.USD","KURE","IE00BPRC5H50.USD","LU0348767384.USD","LU0348784397.USD","LU0417516738.SGD","09926","LU1064131003.USD","LU0348825331.USD","BK1583","IE00B5MMRT66.SGD","LU0561508036.HKD","LU2488822045.USD","BK1161","688331","LU2328871848.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU0348735423.USD","LU0417516902.SGD","LU0348766576.USD","LU1969619763.USD","09995","BK1574","LU1794554557.SGD","LU0634319403.HKD","LU0348783233.USD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680466","title":"股市必读：荣昌生物新发布《H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680466?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:17","pubTimestamp":1789323429,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，荣昌生物报收于114.72元，上涨0.57%，换手率1.39%，成交量4.94万手，成交额5.55亿元。公司公告汇总H股公告荣昌生物制药（烟台）股份有限公司于2026年9月11日通过上海证券交易所集中竞价交易方式回购A股19,000股，每股价格介于113.2元至113.7元之间，总支付金额2,155,248元；本次回购股份拟用于员工股权激励计划，未在回购实施完成公告后3年内使用的部分将予以注销；回购后库存股数量增至254,184股，已发行股份总数不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK1574","LU1969619763.USD","BK0239","LU1064131003.USD","688331","09995","BK1583","LU2148510915.USD","LU2488822045.USD","BK1161","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667050720","title":"每周股票复盘：荣昌生物（688331）上半年净利46.6亿扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2667050720","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667050720?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:34","pubTimestamp":1789238050,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，荣昌生物报收于114.72元，较上周的124.24元下跌7.66%。本周，荣昌生物9月8日盘中最高价报124.22元。本周关注点来自机构调研要点：2026年上半年净利润为46.6亿元，同比实现扭亏为盈。研发费用为4.1亿元，同比下降36%，主因海外临床试验开支减少。公司已于2026年8月25日披露半年报。2026年9月11日，公司通过集中竞价交易方式购回19,000股A股，每股价格113.2元至113.7元，总支付金额2,155,248元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU2328871848.SGD","BK1574","BK1161","09995","LU2488822045.USD","LU1064130708.USD","LU1064131003.USD","688331","BK1583","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666031833","title":"【私募调研记录】巨杉资产调研云天励飞、荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666031833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666031833?lang=zh_cn&edition=full","pubTime":"2026-09-09 08:13","pubTimestamp":1788912819,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，公司拥有1231项专利，其中发明专利977项，一项获中国专利金奖。2）荣昌生物 调研纪要：2026年上半年营业收入为58.5亿元，同比增长433.11%，商业化销售13.4亿元，同比增长22.3%；销售费用5.5亿元，销售费用率同比下降7个百分点；研发费用4.1亿元，同比下降36%；净利润46.6亿元，同比扭亏为盈。机构简介：巨杉（上海）资产管理有限公司成立于2014年4月，是中国基金业协会会员，具备阳光私募基金管理人资格，及3+3投顾资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026090900007137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","BK1583","LU2328871848.SGD","LU1064131003.USD","BK1161","BK0239","688331","LU2148510915.USD","LU2488822045.USD","LU1064130708.USD","LU1969619763.USD","BK1574","91213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666180303","title":"【私募调研记录】保银投资调研荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666180303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666180303?lang=zh_cn&edition=full","pubTime":"2026-09-09 08:13","pubTimestamp":1788912812,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月8日披露的机构调研信息，知名私募保银投资近期对1家上市公司进行了调研，相关名单如下：1）荣昌生物 调研纪要：2026年上半年营业收入为58.5亿元，同比增长433.11%，商业化销售13.4亿元，同比增长22.3%；销售费用5.5亿元，销售费用率同比下降7个百分点；研发费用4.1亿元，同比下降36%；净利润46.6亿元，同比扭亏为盈。RC18在中国获批IgN和SjD，oMGⅢ期入组完成，海外MG全球Ⅲ期入组中，SjD Q2首例入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026090900007115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","BK1583","LU1064131003.USD","LU1969619763.USD","LU1064130708.USD","LU2488822045.USD","BK1161","BK1574","LU2328871848.SGD","688331","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372367","title":"荣昌生物：8月25日召开分析师会议，华泰证券、国联民生等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666372367?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:27","pubTimestamp":1788888446,"startTime":"0","endTime":"0","summary":"荣昌生物2026年中报显示，上半年度公司主营收入58.53亿元，同比上升433.11%；归母净利润46.62亿元，同比上升1137.06%；扣非净利润43.38亿元，同比上升1073.78%；其中2026年第二季度，公司单季度主营收入51.97亿元，同比上升808.6%；单季度归母净利润43.34亿元，同比上升2317.88%；单季度扣非净利润43.73亿元，同比上升2360.61%；负债率15.57%，投资收益128.7万元，财务费用2449.79万元，毛利率95.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01456","LU1781817850.SGD","LU2148510915.USD","LU2328871848.SGD","BK0239","LU1328615791.USD","BK1574","LU1969619763.USD","LU0531971595.HKD","BK1583","LU0164865239.USD","688331","BK0183","BK1161","601456","BK0028","BK0276","LU0039217434.USD","LU1808992512.USD","LU0871576103.HKD","BK0012","BK1147","BK1564","09995","LU1064131003.USD","LU1580142542.USD","601688","LU1064130708.USD","LU1934453819.USD","LU2488822045.USD","LU1979443071.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374484","title":"股市必读：荣昌生物新发布《荣昌生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374484","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374484?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:03","pubTimestamp":1788887000,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，荣昌生物报收于122.85元，上涨0.08%，换手率1.32%，成交量4.7万手，成交额5.73亿元。公司公告汇总：荣昌生物将于9月16日15:00–17:00通过上证路演中心参加科创板2026年半年度创新药行业集体业绩说明会。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱ir@remegen.com提交问题。说明会结束后可通过上证路演中心查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","09995","159992","BK1583","LU1064131003.USD","BK1574","LU1969619763.USD","688331","LU2488822045.USD","LU2148510915.USD","BK0239","BK1161","LU2328871848.SGD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731933","title":"荣昌生物：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731933","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665731933?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，荣昌生物发布公告称，公司计划于2026年9月16日15：00-17：00参加2026年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","09995","IBBQ","159992","BK1583","MEDX","LU1064131003.USD","BK1574","LU1969619763.USD","KSTR","688331","LU2488822045.USD","LU1064130708.USD","LU2148510915.USD","BK0239","BK1161","LU2328871848.SGD","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800103","title":"东海证券：给予荣昌生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664800103?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:32","pubTimestamp":1788481936,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏近期对荣昌生物进行研究并发布了研究报告《公司简评报告：业绩亮眼，研发国际化加速推进》，给予荣昌生物买入评级。 荣昌生物 投资要点 公司业绩表现靓丽。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为161.61。本文数据来源于东海证券股份有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400007902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","161027","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664536817","title":"荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664536817","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664536817?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:04","pubTimestamp":1788357855,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，荣昌生物报收于123.57元，较前一交易日上涨3.28%，最新总市值为697.52亿元。近日，荣昌生物发布《关于2026年第一次以集中竞价交易方式回购公司股份的进展公告》。公告显示，公司于2026年7月19日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购期限为2026年7月19日至2027年7月18日，拟回购金额为2,500万元至5,000万元，回购价格不超过149元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","688331","LU1064131003.USD","LU1969619763.USD","BK1161","LU2328871848.SGD","BK0239","LU1064130708.USD","BK1574","09995","LU2488822045.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819216","title":"荣昌生物(09995)：截至8月末累计回购4.1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819216","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819216?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:01","pubTimestamp":1788350479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，截至2026年8月31日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份4.1万股，占公司总股本的比例为0.0073%，回购成交的最高价为109.99元/股，最低价为108.30元/股，支付的资金总额为人民币447.67万元(不含交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02846","LU2148510915.USD","LU2328871848.SGD","BK0239","BK1574","LU1969619763.USD","BK1583","83130","688331","BK1161","82846","399300","07233","83188","BK1147","09995","LU1064131003.USD","02827","03130","LU1064130708.USD","159982","03188","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819359","title":"执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819359","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819359?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:38","pubTimestamp":1788349091,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月27日，执行董事王玉晓减持荣昌生物(09995)1.35万股，每股作价81.5352港元，总金额约为110.07万港元。减持后最新持股数目为2227.86万股，最新持股比例为10.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","LU1969619763.USD","BK1161","LU2148510915.USD","LU2488822045.USD","BK1574","BK1583","LU2328871848.SGD","EWH","BK0239","688331","LU1064131003.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791012337816,"stockEarnings":[{"period":"1week","weight":-0.0594},{"period":"1month","weight":-0.0365},{"period":"3month","weight":-0.1645},{"period":"6month","weight":-0.213},{"period":"1year","weight":0.0039},{"period":"ytd","weight":0.5084}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24209人(较上一季度增加22.76%)","perCapita":"14700股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC118、RC278、RC288。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}